CSIMarket
 
Spectrum Pharmaceuticals Inc   (SPPI)
Other Ticker:  
 
 
Price: $1.0300 $0.00 0.000%
Day's High: $1.06 Week Perf: 5.64 %
Day's Low: $ 0.97 30 Day Perf: 8.65 %
Volume (M): 5,931 52 Wk High: $ 1.36
Volume (M$): $ 6,109 52 Wk Avg: $0.96
Open: $1.02 52 Wk Low: $0.65



 Market Capitalization (Millions $) 208
 Shares Outstanding (Millions) 202
 Employees 1
 Revenues (TTM) (Millions $) 26
 Net Income (TTM) (Millions $) -65
 Cash Flow (TTM) (Millions $) -26
 Capital Exp. (TTM) (Millions $) 0

Spectrum Pharmaceuticals Inc
Spectrum Pharmaceuticals Inc. is a biopharmaceutical company that focuses on the development and commercialization of oncology and hematology drug products. The company is headquartered in Irvine, California, and was founded in 198 Spectrum Pharmaceuticals operates in the United States and markets its products internationally.

Spectrum Pharmaceuticals has a diverse pipeline of products in various stages of development. The company's product portfolio includes products for the treatment of hematologic and solid tumor cancers, including non-Hodgkin's lymphoma, leukemia, multiple myeloma, and breast, colon, and lung cancers. The company's lead product is a combination of chemotherapy drugs called Zevalin, which is used to treat non-Hodgkines lymphoma.

The company licensed its first product, Apaziquone, a novel drug for the treatment of bladder cancer, to Allergan in 2015 and obtained a significant upfront payment along with milestone and royalty payments. Spectrum Pharmaceuticals also has a licensing agreement with Taiho Pharmaceutical for the development and commercialization of the oncology drug candidate Fusilev in the United States.

Other products in Spectrum Pharmaceuticalse portfolio include ROLONTIS, which is approved by the US Food and Drug Administration (FDA) for the treatment of neutropenia in patients undergoing chemotherapy, and POZIOTINIB, a drug candidate for the treatment of non-small cell lung cancer. The company is also developing other oncology drugs candidates in the pre-clinical and clinical stage of development.

Spectrum Pharmaceuticals' financial performance over the past few years has been mixed. The company reported a net loss in 2019 and 2020, although its total revenue did increase in 2020. The company has a market capitalization of approximately $350 million as of 202

Overall, Spectrum Pharmaceuticals Inc. is a biopharmaceutical company with a diverse portfolio of products in various stages of development for the treatment of oncology and hematology conditions. The company's strategic partnership with other biopharmaceutical companies and its focus on developing novel therapeutic products positions it well for continued growth in the industry.


   Company Address: Pilot House - Lewis Wharf, 2 Atlantic Ave Boston 2110 MA
   Company Phone Number: 586-3900   Stock Exchange / Ticker: NASDAQ SPPI
   SPPI is expected to report next financial results on March 30, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Spectrum Pharmaceuticals Inc

Spectrum Pharmaceuticals Inc Reports Q1 2023 Revenue of $15.615 Million amidst Concerns over Growing Net Loss

As investors eagerly await Spectrum Pharmaceuticals Inc's latest financial data, the recent announcement of their Q1 2023 revenue of $15.615 million may seem somewhat promising. However, upon closer inspection, it becomes clear that there may be cause for concern as the company also reported a net loss of $-5.007 million in the same period.
This significant loss represents a considerable drop from their reported deficit of $-15.442 million in the same financial reporting period a year ago, indicating that they may be struggling to sustain profitability and drive growth.






 

Spectrum Pharmaceuticals Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com